ZenaTech is racing to become a one-stop shop for commercial drones by buying traditional surveying businesses first, then layering in drones and AI to do the work faster and cheaper. The upside is a fast-growing services base that could turn into a scalable tech platform, but shareholders face real risks from heavy cash burn, deal-making complexity, and frequent share issuance.Read more

Key takeaways Myseum (MYSE) is a micro-cap, pre-scale consumer app business that’s pivoting its identity from “private messaging” toward a privacy-first social sharing ecosystem (Picture Party + Pop-Up Gala + Myseum storage). Its new lead product, Picture Party , addresses a familiar frustration for many users: how to share photos privately without group chats, public social feeds, or loss of control over personal content.Read more

Western governments are pushing police and defense teams to replace Chinese-made drones, and Draganfly aims to be one of the homegrown suppliers that benefits. A recent military trial result, new defense orders, and expanding North American production could unlock fast growth—but reliance on government contracts and tough competition could still trip it up.Read more

Western governments are turning away from Chinese-made drones, and Draganfly aims to be a go-to North American supplier for defense and public safety. The story hinges on fresh military validation, expanding local manufacturing, and whether the company can scale fast enough to win larger contracts before bigger rivals do.Read more

Gaxos.ai is a tiny company that shifted from NFTs to building AI tools for game creators and AI-powered wellness services, and it’s just starting to see real customer activity. The upside hinges on whether its early health pilots and Unity-connected game tools turn into repeatable sales before bigger rivals and fundraising needs get in the way.Read more

Draganfly builds drones for defense, public safety, and other demanding jobs, and it’s positioning itself as a trusted North American option as governments look to replace Chinese-made equipment. Fresh military validation, expanding local manufacturing, and new partnerships could accelerate growth—but reliance on government buying cycles and the challenge of scaling up quickly add real risk.Read more

A tiny drug developer says its lead gel helps cancer patients stay on their treatment by easing painful skin rashes where no approved option exists today. With several other early projects in big disease areas, the real question is whether the next study results and regulators back up the early promise—or whether funding and execution get in the way.Read more

A small medical tech company is trying to replace messy, slow drug tests with a quick fingerprint scan that works on-site and is already used overseas. The big question is whether it can win clearance to enter the huge U.S. market before funding needs and copycat competition catch up.Read more